Navigation Links
ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
Date:5/5/2009

ADDISON, Texas, May 5 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal(TM) Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal(TM), was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance ("SALSA") at the University of Arizona College of Medicine, located in Tucson, Arizona.

The article is titled, "Use of a Nanoflex(TM) powder dressing for wound management following debridement for necrotizing fasciitis in the diabetic foot." The article details the treatment of a diabetic patient with a complex wound that requires multiple debridements and several different treatment modalities. The article reports that the patient was transitioned to Altrazeal(TM) following both negative pressure wound therapy and debridement of necrotic tissue. Observations in the article noted that the patient experienced decreased pain associated with wound dressing changes during weekly treatments using Altrazeal(TM), while new wound bed formed. During the treatment regimen, it was also noted that a large soft-tissue defect within the wound filled in with new granulating tissue while the Altrazeal(TM) dressing was pushed free of the hole.

Commenting on the publication, David Armstrong, DPM, PhD, co-author of the publication and Professor of Surgery and Director of SALSA stated, "We believe this technology to be potentially promising with a good deal of clinical versatility."

Renaat Van den Hooff, President and Chief Executive Officer of ULURU, commented: "We are pleased that the team at University of Arizona was the first to publish clinical evidence on the use of Altrazeal(TM) in a clinical setting. We believe this publication to be the first of many detailed scientific publications on Altrazeal(TM) used in clinical settings."

The citation for the publication is: Fitzgerald, R, Bharara, M, Mills, J, Armstrong, DG (2009); "Use of a Nanoflex(TM) powder dressing for wound management following debridement for necrotizing fasciitis in the diabetic foot" International Wound Journal, 6(2): 133-139. Requests for permission to reprint material from this journal should be addressed to:

    Journals Rights & Permissions Controller
    Blackwell Publishing
    9600 Garsington Road
    Oxford OX4 2DQ
    UK
    Email: JournalsRights@oxon.blackwellpublishing.com

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU, please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, patient comfort, pain management, ease of application, success in wound healing, and suitability of Altrazeal(TM) and Altrazeal(TM) Silver, the expectation that further scientific publications relating to Altrazeal(TM) will be published and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
2. ULURU Inc. (ULURU) Dealing Disclosure Requirements
3. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
5. ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
6. ULURU Inc. Announces Senior Management Change
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2008 and to Provide a Business Update
8. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
9. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
10. ULURU Inc. Announces Poster Presentations at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
11. ULURU Inc. to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical ... to studying to become a nun. Now, she writes about God, when she isn’t swimming ... Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look at ...
(Date:2/27/2017)... N. Y. (PRWEB) , ... February 27, 2017 , ... ... ( ILADS ) has disclosed that despite scientific studies, the Center for Disease Control ... chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into a ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an extension of ... to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite ... globally recognised standard that sets out requirements for the technical competence of testing ...
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Hemophilia market? What are the unit prices and ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
Breaking Medicine Technology: